Core Viewpoint - The stock price of Mirxes, a leader in gastric cancer early screening, surged by 7.77% due to significant commercial breakthroughs in both Thailand and China markets [1] Domestic Market Developments - Mirxes has partnered with China National Railway Group to provide gastric cancer early screening services for its employees, marking a successful entry into the health management market of large domestic enterprises [1] - This collaboration is seen as a significant demonstration of the company's innovative product capabilities [1] International Market Expansion - The company has established a strategic partnership with BDMS, the largest medical group in Thailand, to promote gastric cancer early screening in the high-end market [1] - BDMS's extensive influence in Southeast Asia is viewed as a crucial breakthrough for the international commercialization of Mirxes' products [1] Market Recognition - The acquisition of two prestigious industry benchmark clients in both countries reflects the market's recognition of Mirxes' technological strength in the gastric cancer early screening field [1] - The stock price increase indicates growing market attention towards the company's valuation and growth potential [1]